MGF Results Timeline: What Studies Measured, and When

What a "results timeline" would require, and what exists

A results timeline, in the strict sense, requires a study that administered a compound, defined endpoints in advance, and measured those endpoints at stated intervals, week 2, week 6, month 3, in a defined population. For mechano growth factor (MGF), the common name for a splice variant of insulin-like growth factor 1 discussed in skeletal-muscle biology, the verified literature on this page contains no such administration trial in humans. That absence is the single most important fact on the page, and it is stated plainly rather than filled in with inference.

What the record does contain is a human study of endogenous MGF gene expression, animal work on how fast muscle protein-metabolism signalling changes under unloading, and methodology work on how muscle mass itself is quantified in people. Those are three different kinds of clock, and conflating them is how unsupported "by week six" claims are generated. Each is described below with the timepoint logic it actually used.

The human measurement: MGF mRNA after orthognathic surgery

The one human paper in this set that measured MGF directly examined MGF- and myostatin-mRNA regulation in masseter muscle after orthognathic surgery (PMID 18567511). The study looked at transcript regulation in a muscle subjected to a surgical change in mechanical loading, that is, it observed how the body's own MGF message behaved, and researchers reported on MGF alongside myostatin, a negative regulator of muscle mass, in the same muscle (PMID 18567511).

Several things follow from that design. First, the exposure was surgery and the altered loading that accompanies it, not an injected peptide; no dose exists to attach a timeline to. Second, the readout was messenger RNA, a molecular signal, not strength, lean mass, injury recovery or any outcome a person would notice. Third, because the measurement was of transcript levels, the study speaks to the regulation of a gene product in human muscle rather than to any effect of giving MGF from outside the body (PMID 18567511).

Why mRNA timing is not outcome timing

Gene-expression studies answer "when did the signal move?" Outcome studies answer "when did the person change?" The gap between the two can be large and is not fixed. A transcript can rise and fall within hours of a mechanical stimulus while measurable tissue change, if any occurs, lags by weeks. Nothing in the masseter study converts a transcript observation into a functional timeline (PMID 18567511), and no paper in this citation set performs that conversion.

Animal timing designs: how quickly signalling shifts under unloading

For a sense of how short the window can be in preclinical muscle work, a rodent study of short-term creatine supplementation examined protein metabolism signalling in hindlimb suspension, a standard model of muscle unloading, and researchers reported changes in protein metabolism signalling over that short-term supplementation period (PMID 31596311). This is animal work and it concerned creatine, not MGF; it is included only to illustrate that molecular signalling endpoints in muscle are commonly assessed over days-to-short-weeks horizons rather than months, and that the compound, species and model all define what the resulting timeline means (PMID 31596311).

Preclinical designs in other tissues follow comparable fixed-interval logic. A study of cancellous bone microstructure in fluorosis rats used microstructural analysis as the terminal endpoint in an animal model (PMID 36640257), again demonstrating that an animal timeline is set by when the tissue is harvested and analysed, not by when a living subject might notice anything. Neither rodent study involved MGF administration, and neither can be read forward into a human schedule.

How muscle mass is measured in people, and what that implies for timelines

Any claim that something changed by a given week depends on a measurement sensitive enough to detect it. Work in nephrology validated glomerular filtration of creatinine as a novel index of muscle mass among older adults (PMID 39674339), which underlines that muscle mass in humans is estimated through indices and imaging rather than observed directly, and that validation of such an index is itself a research question. The study was conducted among older adults and addressed measurement validity, not the effect of any peptide (PMID 39674339).

The practical consequence is that timeline statements are bounded by measurement precision. If an index carries meaningful variability, small short-horizon changes may be indistinguishable from noise, which is one reason credible trials pre-specify both the endpoint and the interval at which it is read (PMID 39674339).

"MGF" in indexed literature often means something else entirely

Database searches for MGF return a large body of work in which the abbreviation refers to mangiferin, a plant polyphenol, not to the IGF-1 splice variant. Green nanotechnology work described MGF-AuNPs, mangiferin-functionalised gold nanoparticles, for immunomodulatory intervention in prostate cancer therapy (PMID 34408231). Separately, researchers reported that mangiferin alleviated renal inflammatory injury in spontaneously hypertensive rats by inhibiting MCP-1/CCR2 signalling (PMID 38094010), an animal finding in a disease model unconnected to muscle growth.

This matters for timeline questions because oncology and nephrology abstracts using the same three letters can be mistaken for muscle-peptide evidence. The prostate-cancer nanoparticle work concerned immunomodulatory intervention (PMID 34408231), and the hypertensive-rat work concerned renal inflammatory injury (PMID 38094010); neither reports anything about hypertrophy, recovery or performance over time.

What was measured, and when: a comparison

Reading timeline claims critically

Claims of the form "effects appear at week X" should be traceable to a specific design. Useful questions include:

• Was anything administered? The human MGF measurement in this set followed surgery and observed endogenous transcript regulation rather than an administered peptide (PMID 18567511).
• What species? Short-horizon signalling results in unloaded rodents came from an animal model (PMID 31596311).
• What endpoint? Transcript levels, bone microstructure and a validated mass index are not interchangeable readouts (PMID 36640257, PMID 39674339).
• Which MGF? Mangiferin papers share the abbreviation but not the subject matter (PMID 38094010).

Adverse Events: What Studies Report

No paper in this verified set administered an MGF peptide to humans, so none reports adverse events, tolerability or safety signals for such use. The human MGF paper measured transcript regulation in masseter muscle after orthognathic surgery and did not involve peptide administration (PMID 18567511). Safety observations that appear in nearby literature belong to different compounds and contexts: mangiferin work was conducted in a rodent hypertension model (PMID 38094010) and in preclinical oncology (PMID 34408231), and rodent creatine work addressed protein metabolism signalling under unloading (PMID 31596311). Absence of reported adverse events in papers that never administered a compound is not evidence of safety; it is simply absence of data.

Gaps in the evidence

Three gaps define the current picture. First, there is no dose: no paper in this set states an administered quantity of MGF peptide in humans or animals, so none is reproduced here. Second, there is no interval schedule: the human MGF data concern post-surgical regulation of endogenous transcripts (PMID 18567511), not a protocol with scheduled follow-up visits. Third, there is no functional outcome: strength, body composition and recovery were not endpoints in that work (PMID 18567511), and the measurement-science literature shows that even quantifying muscle mass in older adults required dedicated validation (PMID 39674339).

Until administration studies with pre-specified endpoints and intervals exist, any stated week-by-week progression for MGF is extrapolation rather than evidence. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question, symptom or decision. Research-chemical status, legality and availability vary by jurisdiction and are outside the scope of the studies summarised here.

Summary of the literature position

Across the cited record, the only human measurement of MGF concerned mRNA regulation in masseter muscle after orthognathic surgery (PMID 18567511); short-horizon muscle signalling data came from an unloaded rodent model with a different compound (PMID 31596311); human muscle-mass quantification was addressed as a measurement-validation problem in older adults (PMID 39674339); and a substantial share of "MGF" citations refer to mangiferin in oncology and nephrology contexts (PMID 34408231, PMID 38094010). No timeline of results for an administered MGF peptide appears in these papers.

References

• MGF- and myostatin-mRNA regulation in masseter muscle after orthognathic surgery (Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, 2008)
• Short-term creatine supplementation changes protein metabolism signaling in hindlimb suspension (Brazilian Journal of Medical and Biological Research, 2019)
• Glomerular Filtration of Creatinine: Validation of a Novel Index of Muscle Mass Among Older Adults (American Journal of Kidney Diseases, 2025)
• Microstructural Analysis of Cancellous Bone in Fluorosis Rats (Biological Trace Element Research, 2023)
• Green nanotechnology of MGF-AuNPs for immunomodulatory intervention in prostate cancer therapy (Scientific Reports, 2021)
• Mangiferin alleviates renal inflammatory injury in spontaneously hypertensive rats by inhibiting MCP-1/CCR2 signaling pathway (Chinese Herbal Medicines, 2023)